# A Study of Trifluridine/Tipiracil in Triple Negative Metastatic Breast Cancer

> **NCT04149444** · PHASE2 · WITHDRAWN · sponsor: **AHS Cancer Control Alberta**

## Conditions studied

- Metastatic Triple Negative Breast Cancer

## Interventions

- **DRUG:** Trifluridine/Tipiracil

## Key facts

- **NCT ID:** NCT04149444
- **Lead sponsor:** AHS Cancer Control Alberta
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-02
- **Primary completion:** 2020-06-09
- **Final completion:** 2020-06-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor withdrew support
- **Last updated:** 2020-06-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04149444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04149444, "A Study of Trifluridine/Tipiracil in Triple Negative Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04149444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*